Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,645 Cr.
 - Current Price ₹ 432
 - High / Low ₹ 582 / 281
 - Stock P/E
 - Book Value ₹ 51.2
 - Dividend Yield 0.00 %
 - ROCE -2.14 %
 - ROE -4.76 %
 - Face Value ₹ 1.00
 
Pros
- Company is expected to give good quarter
 
Cons
- Stock is trading at 8.43 times its book value
 - Company has low interest coverage ratio.
 - Company has a low return on equity of -10.3% over last 3 years.
 - Earnings include an other income of Rs.17.8 Cr.
 
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 498 | 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | 310 | 365 | |
| 586 | 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | 317 | 365 | |
| Operating Profit | -88 | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 | -7 | 1 | 
| OPM % | -18% | 10% | 17% | 13% | -4% | -152% | -57% | 0% | -31% | -24% | 4% | -2% | 0% | 
| 304 | 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | 17 | 18 | |
| Interest | 148 | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 | 15 | 18 | 
| Depreciation | 69 | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 | 20 | 20 | 
| Profit before tax | -0 | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 | -26 | -20 | 
| Tax % | 0% | 3% | 38% | -14% | 17% | 29% | 13% | 12% | 0% | 40% | 16% | -42% | |
| -0 | -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | -15 | -8 | |
| EPS in Rs | -0.07 | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 | -2.48 | -1.33 | 
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -8% | 
| 5 Years: | 14% | 
| 3 Years: | 10% | 
| TTM: | 12% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% | 
| 5 Years: | 13% | 
| 3 Years: | 22% | 
| TTM: | 29% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% | 
| 5 Years: | 20% | 
| 3 Years: | 45% | 
| 1 Year: | 20% | 
| Return on Equity | |
|---|---|
| 10 Years: | -16% | 
| 5 Years: | -10% | 
| 3 Years: | -10% | 
| Last Year: | -5% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 
| Reserves | 556 | 517 | 518 | 450 | 382 | 412 | 887 | 502 | 409 | 320 | 323 | 308 | 
| 990 | 1,031 | 1,035 | 1,023 | 970 | 689 | 67 | 65 | 84 | 102 | 125 | 228 | |
| 334 | 325 | 248 | 303 | 316 | 335 | 179 | 217 | 263 | 296 | 300 | 327 | |
| Total Liabilities | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 
| 1,086 | 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 423 | 416 | |
| CWIP | 26 | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 97 | 119 | 
| Investments | 394 | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 
| 380 | 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | 334 | |
| Total Assets | 1,886 | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 33 | 4 | |
| -18 | -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -47 | -61 | |
| -38 | -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | 90 | |
| Net Cash Flow | -3 | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 | 33 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 | 25 | 
| Inventory Days | 310 | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 | 541 | 
| Days Payable | 397 | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 299 | 586 | 
| Cash Conversion Cycle | -20 | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -10 | -21 | 
| Working Capital Days | -403 | -229 | -80 | -133 | -682 | -49 | 892 | 4 | -63 | -135 | -79 | -141 | 
| ROCE % | -9% | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% | 4% | -2% | 
Documents
Announcements
- 
        
          Announcement under Regulation 30 (LODR)-Newspaper Publication
          
            17 Oct - Newspaper copies regarding Notice intimating the shareholders about the opening of a Special Window for Re-lodgement of transfer requests of physical shares
 - 
        
          Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
          
            9 Oct - Accepted LOA to supply bivalent OPV to CMSS worth Rs.127.20 Crore over 90–480 days.
 - 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            7 Oct - Panacea Biotec: RTA certificate dated Oct 03, 2025 confirming Reg 74(5) compliance for quarter ended Sep 30, 2025.
 - Demat Status Report For The Month Of September 2025 7 Oct
 - 
        
          Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
          
            3 Oct - UNICEF long-term bOPV supply award ~US$35.65m for Q2 CY2026 and CY2027 (Apr 2026–Mar 2030).
 
Annual reports
- 
    
      Financial Year 2025
      from bse
 - 
    
      Financial Year 2024
      from bse
 - 
    
      Financial Year 2023
      from bse
 - 
    
      Financial Year 2022
      from bse
 - 
    
      Financial Year 2021
      from bse
 - 
    
      Financial Year 2020
      from bse
 - 
    
      Financial Year 2019
      from bse
 - 
    
      Financial Year 2018
      from bse
 - 
    
      Financial Year 2017
      from bse
 - 
    
      Financial Year 2016
      from bse
 - 
    
      Financial Year 2015
      from bse
 - 
    
      Financial Year 2014
      from bse
 - 
    
      Financial Year 2013
      from nse
 - 
    
      Financial Year 2013
      from bse
 - 
    
      Financial Year 2012
      from nse
 
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix